In ₹ Crore except Per Share Latest Annual	YATHARTH FY26	MAXHEALTH FY26	MEDANTA FY26	FORTIS FY26	Peer Average
Valuation — at last close
P/E	◆ 50.73×	57.39×	62.76×	54.70×	58.28× -13%
P/B	◆ 4.92×	7.71×	8.82×	5.76×	7.43× -34%
EV/EBITDA	30.42×	38.17×	38.09×	◆ 28.57×	34.94× -13%
Market Cap	₹8,896 Cr	₹82,828 Cr	₹34,922 Cr	₹56,992 Cr	₹58,247 Cr -85%
Growth
Revenue CAGR 3Y	◆ 48.11%	22.43%	17.85%	13.17%	17.82% +170%
Revenue CAGR 5Y	—	◆ 27.30%	—	17.76%	22.53%
Net Income CAGR 3Y	◆ 38.45%	9.34%	19.33%	18.91%	15.86% +142%
Revenue YoY (latest Q)	◆ 52.33%	16.70%	26.50%	17.46%	20.22% +159%
Net Income YoY (latest Q)	◆ 8.05%	4.87%	-1.09%	2.26%	2.01% +300%
Profitability
EBITDA Margin	24.20%	◆ 26.79%	20.84%	22.84%	23.49% +3%
Net Income Margin	14.11%	◆ 17.23%	12.56%	11.66%	13.82% +2%
Return on Common Equity	9.98%	14.33%	◆ 15.15%	11.08%	13.52% -26%
Return on Capital Employed	10.91%	12.63%	◆ 14.78%	12.62%	13.34% -18%
Return on Assets	8.49%	8.89%	◆ 10.38%	7.18%	8.82% -4%
Credit & Quality
Total Debt/Equity	◆ 0.14×	0.32×	0.30×	0.28×	0.30× -53%
Interest Coverage	◆ 31.26×	7.64×	8.80×	5.20×	7.21× +333%
Scale — latest FY
Revenue / Total Income	₹1,207 Cr	₹8,373 Cr	₹4,410 Cr	₹9,128 Cr	₹7,304 Cr -83%
Net Income	₹170 Cr	₹1,442 Cr	₹554 Cr	₹1,064 Cr	₹1,020 Cr -83%
Total Assets	₹2,282 Cr	₹17,231 Cr	₹5,905 Cr	₹15,966 Cr	₹13,034 Cr -82%
EPS	₹18.2	₹14.83	₹20.71	₹13.8	₹16.45 +11%
Book Value per Share	₹187.55	₹110.43	₹147.44	₹131.07	₹129.65 +45%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.